← Eichor
Condition: Hairy Cell Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hairy Cell Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · 4 location(s) · Newave Pharmaceutical Inc · NCT04775745Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patie
Phase N/A · 3 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06774677Hairy Cell Leukemia Patient Data Registry
Phase N/A · 8 location(s) · Ohio State University Comprehensive Cancer Center · NCT02560883Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Phase 1/Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT069651143'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04322383Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Phase 2 · 21 location(s) · National Cancer Institute (NCI) · NCT06311227Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care Management
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06764524Assessment of Disease Burden in Hairy Cell Leukemia
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06781515Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00412594A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT06561360Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Phase 2/Phase 3 · 76 location(s) · University of Giessen · NCT02131753Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Varian
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04815356Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01087333
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.